Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials

Fuente: arXiv
Saved in:
Bibliographic Details
Main Authors: Long, James P., Roy, Abhishikta, Irajizad, Ehsan, Do, Kim-Anh, Shen, Yu
Format: Preprint
Published: 2025
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866911094810869760
author Long, James P.
Roy, Abhishikta
Irajizad, Ehsan
Do, Kim-Anh
Shen, Yu
author_facet Long, James P.
Roy, Abhishikta
Irajizad, Ehsan
Do, Kim-Anh
Shen, Yu
contents In meta-analytic modeling, the functional relationship between a primary and surrogate endpoint is estimated using summary data from a set of completed clinical trials. Parameters in the meta-analytic model are used to assess the quality of the proposed surrogate. Recently, meta-analytic models have been employed to evaluate whether late-stage cancer incidence can serve as a surrogate for cancer mortality in cancer screening trials. A major challenge in meta-analytic models is that uncertainty of trial-level estimates affects the evaluation of surrogacy, since each trial provides only estimates of the primary and surrogate endpoints rather than their true parameter values. In this work, we show via simulation and theory that trial-level estimate uncertainty may bias the results of meta-analytic models towards positive findings of the quality of the surrogate. We focus on cancer screening trials and the late stage incidence surrogate. We reassess correlations between primary and surrogate endpoints in Ovarian cancer screening trials. Our findings indicate that completed trials provide limited information regarding quality of the late-stage incidence surrogate. These results support restricting meta-analytic regression usage to settings where trial-level estimate uncertainty is incorporated into the model.
format Preprint
id arxiv_https___arxiv_org_abs_2508_04633
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
Long, James P.
Roy, Abhishikta
Irajizad, Ehsan
Do, Kim-Anh
Shen, Yu
Methodology
Applications
In meta-analytic modeling, the functional relationship between a primary and surrogate endpoint is estimated using summary data from a set of completed clinical trials. Parameters in the meta-analytic model are used to assess the quality of the proposed surrogate. Recently, meta-analytic models have been employed to evaluate whether late-stage cancer incidence can serve as a surrogate for cancer mortality in cancer screening trials. A major challenge in meta-analytic models is that uncertainty of trial-level estimates affects the evaluation of surrogacy, since each trial provides only estimates of the primary and surrogate endpoints rather than their true parameter values. In this work, we show via simulation and theory that trial-level estimate uncertainty may bias the results of meta-analytic models towards positive findings of the quality of the surrogate. We focus on cancer screening trials and the late stage incidence surrogate. We reassess correlations between primary and surrogate endpoints in Ovarian cancer screening trials. Our findings indicate that completed trials provide limited information regarding quality of the late-stage incidence surrogate. These results support restricting meta-analytic regression usage to settings where trial-level estimate uncertainty is incorporated into the model.
title Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
topic Methodology
Applications
url https://arxiv.org/abs/2508.04633